Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer

被引：0
|
作者：
Yoshinori Munemoto
Mitsuro Kanda
Keiichiro Ishibashi
Taishi Hata
Michiya Kobayashi
Junichi Hasegawa
Mutsumi Fukunaga
Akinori Takagane
Toshio Otsuji
Yasuhiro Miyake
Michitaka Nagase
Junichi Sakamoto
Masaki Matsuoka
Koji Oba
Hideyuki Mishima
机构：
[1] Fukuiken Saiseikai Hospital,Department of Surgery
[2] Nagoya University Graduate School of Medicine,Department of Gastroenterological Surgery (Surgery II)
[3] Saitama Medical Center,Department of Digestive Tract and General Surgery
[4] Saitama Medical University,Department of Gastroenterological Surgery
[5] Osaka University Graduate School of Medicine,Department of Human Health and Medical Sciences
[6] Kochi Medical School,Department of Surgery
[7] Osaka Rosai Hospital,Department of Surgery
[8] Hyogo Prefectural Nishinomiya Hospital,Department of Internal Medicine
[9] Surgical Division,Department of Surgery
[10] Hakodate Goryoukaku Hospital,Department of Surgical Oncology
[11] Dongo Hospital,Department of Biostatistics
[12] Minoh City Hospital Gastrointestinal Research Center,undefined
[13] Gifu University Graduate School of Medicine,undefined
[14] Director,undefined
[15] Tokai Central Hospital,undefined
[16] Matsuoka Clinic,undefined
[17] School of Public Health,undefined
[18] Tokyo University Graduate School of Medicine,undefined
[19] Interfaculty Initiative in Information Studies,undefined
[20] Tokyo University,undefined
[21] Unit of Cancer Center,undefined
[22] Aichi Medical University,undefined
来源：
BMC Cancer | / 15卷
关键词：
Colorectal cancer; Elderly; Bevacizumab; XELOX;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer
    Karacetin, D.
    Yalcin, B.
    Okten, B.
    Ozturk, S.
    Maral, O.
    Incekara, O.
    JOURNAL OF BUON, 2009, 14 (04): : 605 - 608
  • [32] Capecitabine and oxaliplatin (XELOX) as first line treatment for patients with metastatic colorectal cancer (MCRC)
    Karacetin, D.
    Maral, O.
    Yalcyn, B.
    Okten, B.
    Incekara, O.
    ANNALS OF ONCOLOGY, 2006, 17 : 73 - 73
  • [33] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer
    Sato, Yasushi
    Ohnuma, Hiroyuki
    Hirakawa, Masahiro
    Takahashi, Minoru
    Osuga, Takahiro
    Okagawa, Yutaka
    Murase, Kazuyuki
    Takada, Kohichi
    Kawano, Yutaka
    Iyama, Satoshi
    Hayashi, Tsuyoshi
    Sato, Tsutomu
    Miyanishi, Koji
    Takimoto, Rishu
    Kobune, Masayoshi
    Okita, Kenji
    Mizuguchi, Toru
    Furuhata, Tomohisa
    Hirata, Koichi
    Kato, Junji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 587 - 594
  • [34] Phase II Study of Bevacizumab, Capecitabine, and Oxaliplatin Followed by Bevacizumab Plus Erlotinib as First-Line Therapy in Metastatic Colorectal Cancer
    Munoz, Alberto
    Pericay, Caries
    Garcia-Giron, Carlos
    Alonso, Vicente
    Duenas, Rosario
    Cirera, Luis
    Rivera, Fernando
    Falco, Esther
    Alvarez Bustos, Inaki
    Salud, Antonieta
    ONCOLOGY RESEARCH, 2013, 21 (04) : 181 - 191
  • [35] OXALIPLATIN AND CAPECITABINE (XELOX) PLUS BEVACIZUMAB (BEVA) FOR ELDERLY PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC): BOXE, A PHASE II TRIAL
    Rosati, Gerardo
    Cordio, Stefano
    Leo, Silvana
    Daniele, Bruno
    Butera, Alfredo
    ANNALS OF ONCOLOGY, 2011, 22 : v104 - v104
  • [36] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer
    Yasushi Sato
    Hiroyuki Ohnuma
    Masahiro Hirakawa
    Minoru Takahashi
    Takahiro Osuga
    Yutaka Okagawa
    Kazuyuki Murase
    Kohichi Takada
    Yutaka Kawano
    Satoshi Iyama
    Tsuyoshi Hayashi
    Tsutomu Sato
    Koji Miyanishi
    Rishu Takimoto
    Masayoshi Kobune
    Kenji Okita
    Toru Mizuguchi
    Tomohisa Furuhata
    Koichi Hirata
    Junji Kato
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 587 - 594
  • [37] Safety of capecitabine plus bevacizumab in heavily treated patients with metastatic colorectal cancer (MCRC)
    Adamo, Vincenzo
    Festa, Vincenzo
    Restuccia, Eleonora
    Chiofalo, Giuseppe
    Maisano, Carmelo
    Picciotto, Maria
    Alafaci, Elisabetta
    Tortora, Giampaolo
    ANNALS OF ONCOLOGY, 2007, 18 : 16 - 17
  • [38] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    J Feliu
    M J Safont
    A Salud
    F Losa
    C García-Girón
    C Bosch
    P Escudero
    R López
    C Madroñal
    M Bolaños
    M Gil
    A Llombart
    J Castro-Carpeño
    M González-Barón
    British Journal of Cancer, 2010, 102 : 1468 - 1473
  • [39] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    Feliu, J.
    Safont, M. J.
    Salud, A.
    Losa, F.
    Garcia-Giron, C.
    Bosch, C.
    Escudero, P.
    Lopez, R.
    Madronal, C.
    Bolanos, M.
    Gil, M.
    Llombart, A.
    Castro-Carpeno, J.
    Gonzalez-Baron, M.
    BRITISH JOURNAL OF CANCER, 2010, 102 (10) : 1468 - 1473
  • [40] A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer A Prospective, Multicenter Trial of the Korean Cancer Study Group
    Hong, Yong Sang
    Lee, Sung Sook
    Kim, Kyu-pyo
    Lee, Jae-Lyun
    Kang, Yoon-Koo
    Shin, Sang Joon
    Ahn, Joong Bae
    Jung, Kyung Hae
    Im, Seock-Ah
    Kim, Tae-You
    Kim, Jee Hyun
    Park, Young Suk
    Kim, Tae Won
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (01): : 19 - 23
12345